FLGT Fulgent Genetics
- 22.447
- +0.127+0.57%
Fulgent Genetics News
Brixton Biosciences Announces $33M in Series B Funding to Advance Novel Technology for the Treatment of Pain
Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
Collaboration aims to accelerate the development of personalized therapies and transform patient care through the use of precision medicine TAMPA, Fla. & LOS ANGELES--(BUSINESS WIRE)--May 14, 2024-- M
Earnings Release: Here's Why Analysts Cut Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target To US$26.67
Investors in Fulgent Genetics, Inc. (NASDAQ:FLGT) had a good week, as its shares rose 4.4% to close at US$21.49 following the release of its first-quarter results. It looks like the results wer
Analysts Have Conflicting Sentiments on These Healthcare Companies: Fulgent Genetics (FLGT), Cigna (CI) and PROCEPT BioRobotics (PRCT)
Fulgent Genetics Inc (FLGT) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges ...
Fulgent Genetics Inc (FLGT) Q1 2024 Earnings: Misses Analyst Forecasts With Wider Losses
Fulgent Genetics Releases Updated Investor Presentation
Fulgent Genetics Reports Mixed Q1 Results; Reaffirms FY24 Outlook
Fulgent Forecasts 2024 Core Revenue Of Approximately $280M Versus Consensus Of $279.356M, With Adjusted EPS Loss Of Approximately $(1.05) Versus Consensus Of $(1.06)
Fulgent Forecasts 2024 Core Revenue Of Approximately $280M Versus Consensus Of $279.356M, With Adjusted EPS Loss Of Approximately $(1.05) Versus Consensus Of $(1.06)
Fulgent Genetics Q1 2024 Adj EPS $(0.01) May Not Be Comparable To $(0.32) Estimate, Sales $64.485M Miss $65.363M Estimate
Fulgent Genetics (NASDAQ:FLGT) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.32) by 96.88 percent. This is a 95.45 percent increase over losses of $(0
Earnings Flash (FLGT) FULGENT GENETICS Posts Q1 Revenue $64.5M
07:01 AM EDT, 05/03/2024 (MT Newswires) -- Earnings Flash (FLGT) FULGENT GENETICS Posts Q1 Revenue $64.5M
Fulgent Genetics 1Q Loss/Shr 45c >FLGT
Fulgent Genetics 1Q Loss/Shr 45c >FLGT
Press Release: Fulgent Reports First Quarter 2024 Financial Results
Fulgent Reports First Quarter 2024 Financial Results -- Total Revenue of $64.5 million -- Core Revenue grows 1% year-over-year to $63.2 million -- Reiterates Full Year 2024 Core Revenue G
Fulgent Reports First Quarter 2024 Financial Results
Total Revenue of $64.5 million Core Revenue grows 1% year-over-year to $63.2 million Reiterates Full Year 2024 Core Revenue Guidance of $280 million EL MONTE, Calif.--(BUSINESS WIRE)--May 3, 2024--
Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024
EL MONTE, Calif.--(BUSINESS WIRE)--Apr. 11, 2024-- Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business a
Reproductive Genetics Market Analysis Report 2024-2032, Featuring Bangkok Genomics Innovation, Centogene, Fulgent Genetics, Igenomix, Invitae, PerkinElmer and Thermo Fisher Scientific
Fulgent Genetics Is Maintained at Neutral by Piper Sandler
Fulgent Genetics Is Maintained at Neutral by Piper Sandler
Piper Sandler Maintains Neutral on Fulgent Genetics, Lowers Price Target to $25
Piper Sandler analyst David Westenberg maintains Fulgent Genetics with a Neutral and lowers the price target from $28 to $25.
Fulgent Genetics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/06/2024 7.67% Piper Sandler $28 → $25 Maintains Neutral 12/07/2023 50.73% UBS → $35 Initiates Coverage
Piper Sandler Sticks to Its Hold Rating for Fulgent Genetics (FLGT)
Analysis
Price Target
No Data
